• Home
• Partneringtools
• Reports

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Consulting
• Jobs
• Forums

• About us
• Products
• Newsletter

Pharmalicensing Ltd
is a division of

— N. BILLERICA, Massachusetts, July 18

N. BILLERICA, Massachusetts, July 18 /PRNewswire/ -- Seahorse Bioscience, Inc., leaders in real-time measurement of cellular bioenergetics announced today the receipt of The European Association for the Study of Obesity (EASO) poster award at the 16th European Congress on Obesity (ECO 2008) May 14-17, 2008 in Geneva, Switzerland.

The poster, Mechanism of Action of Metformin on Insulin Sensitization: Selective Fatty Acid Oxidation (FAO) over Glucose Oxidation via Inhibition of Complex I and Activation of AMP-activated protein kinase in C2C12 myocytes presented by author Dr. Min Wu of Seahorse Bioscience, was one of three posters to win the prestigious 2008 EASO Poster Prize. Poster Prize winners have already been listed on the EASO website (www.easoobesity.org) and will be highlighted in the Association's next e-newsletter.

"We are very pleased that EASO recognized our work on cellular mechanism of action of metformin," said David Ferrick, Vice President of Biology. "It is the bioenergetic analysis of fuel substrate selections that revealed the mechanism of action in different cell types, an analysis with the potential to be very powerful in the understanding and treatment of many other age-related diseases."

"It is unusual for an instrument manufacturer to be recognized for scientific contribution but Seahorse XF technology enables novel discoveries by bringing to light the importance of energy producing pathways of the cell," said Steven Chomicz, Vice President of Sales and Marketing for Seahorse Bioscience. "Dr. Wu used the features of the XF24 extracellular flux analyzer to perform an eloquent experiment which revealed metformin's, heretofore, unknown mechanism of action. This potential for award winning discoveries is why Seahorse XF technology is used by leading bioenergetic labs worldwide."

About Seahorse Bioscience, Inc.

Seahorse Bioscience is changing cancer, obesity, diabetes and age-related drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

If you would like more information about Seahorse Bioscience, Inc., or would like to schedule a meeting with Steve Chomicz, please contact Kristine Hunt at +1-978-671-1610.

Seahorse Bioscience, Inc. Media Contact: Kristine Hunt Phone: +1-978-671-1610 Web site: http://www.seahorsebio.com http://www.easoobesity.org

• Seahorse Bioscience

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us